Skip to content
★ Sign in to follow
Jiangsu Jibeier Pharmaceutical Co., Ltd. logo

Jiangsu Jibeier Pharmaceutical Co., Ltd. Stock: price and insider trades · China

吉贝尔

CN·Mcap CN¥5.4BHealth Care

No insider purchase over the last 90 days. The latest, by 烜鼎飞扬私募证券投资基金, was filed 20 Dec 2022.

Jiangsu Jibeier Pharmaceutical Co., Ltd.: what insiders have been doing

Every trade that managers of Jiangsu Jibeier Pharmaceutical Co., Ltd. disclose to SSE / SZSE (CSRC) is tracked on this page. The company sits in the Health Care sector. Nothing new has been filed by managers of Jiangsu Jibeier Pharmaceutical Co., Ltd. in twelve months, the latest record being from 18 July 2025.

Over the whole record (from 2022), the tally stands at 1 purchase and 8 sales.

Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and Vetoquinol SA. Every figure here comes from the filings published by SSE / SZSE (CSRC) and describes the past, not future prices; it is not investment advice.

Insider Decl.
9
Thresholds
n/a
Buy Volume
€12M
1 ops. · all time
Sell Volume
€14M
8 ops. · all time

Who traded when

BuySale
吴修艮3 sales
李海岛2 sales
李召广1 sale
胡涛1 sale

Since the insiders bought

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 5,801 of 26,914 companies
66.1
score / 100
Value
48
Quality
84
FCF yld2.5%
Earn yld4.9%
EV/EBITDA16.8x
ROE8.5%
Gross mgn89%
Net mgn27%
Debt/EBITDA0.1x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

CN¥26.63
Analyst consensus
·
Income statement
RevenueCN¥966.1M
Gross profitCN¥864.2M89% margin
EBITDACN¥319.2M33% margin
Net incomeCN¥261.6M21.1% margin
Valuation
PER (trailing)25.1x
P/Book2.1x
Beta0.27
Balance sheet & cash
Market capCN¥5.4B
Total debtCN¥18.7M
Free Cash FlowCN¥133.7M
Debt / Equity0%
Profitability & ownership
ROE8.5%
ROA5.5%
% insiders70.3%
% institutions3.1%
Last declaration on 18 July 2025
Declarations9 total
  • ▼
    核心技术人员Executives
    206,169 CNY24SSE
    5,700 shares70.0% of flowA股XSHGSSE:173000009249714100
  • ▼
    核心技术人员Executives
    5M CNY22SSE
    176,769 shares85.1% of flowA股XSHGSSE:173000009200785900
  • ▼
    核心技术人员Executives
    532,177 CNY18SSE
    17,627 shares8.5% of flowA股XSHGSSE:173000009186992300
  • ▼
    核心技术人员Executives
    1M CNY25SSE
    48,600 shares100.0% of flowA股XSHGSSE:173000009180988500
  • ▼
    核心技术人员Executives
    398,166 CNY15SSE
    13,885 shares6.4% of flowA股XSHGSSE:173000009104547330
  • ▼
    核心技术人员Executives
    88,500 CNY17SSE
    3,000 shares30.0% of flowA股XSHGSSE:173000009091192900
  • ▼
    董事Executives
    6M CNY8SSE
    242,275 shares5.8% of flowA股XSHGSSE:173000008956098180
  • ▼
    董事Executives
    89M CNY15SSE
    3,730,000 shares94.2% of flowA股XSHGSSE:173000006147079170
  • ▲
    董事Executives
    89M CNY15SSE
    3,730,000 shares100.0% of flowA股XSHGSSE:173000006144258370
    Canonical exit: 20 Mar 2023 (T+90)

9 of 9 declarations

About Jiangsu Jibeier Pharmaceutical Co., Ltd.

吉贝尔 is a company operating in the healthcare and pharmaceutical sector, listed on the XSHG market. It specializes in the development and marketing of innovative pharmaceutical products.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations